# Genmab Acquires Merus N.V. for Approximately $8 Billion to Add Bispecific Antibody Pipeline

> ma · REPORTED · 2025-06-01

Genmab announced an agreement to acquire Merus N.V. for approximately $8 billion ($97 per share), adding Merus's Phase III EGFRxLGR5 bispecific antibody petosemtamab to its pipeline; the asset holds two Breakthrough Therapy Designations from the FDA for head and neck cancer.

- Company: Genmab
- Sector: biotech
- Primary source: https://xtalks.com/pharma-and-biotech-mas-in-2025-roundup-4105/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.